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Alzheimer’s Disease (AD) and atherosclerosis remain two of the largest public health
burdens in the world today. Although traditionally considered distinct pathological
entities, mounting epidemiologic, clinical and experimental evidence suggests that
cerebrovascular atherosclerosis and AD interact reciprocally to disrupt brain structure
and function. Whereas the hypoperfusion and hypoxia caused by atherosclerosis of
cerebral vessels may enhance the production of amyloid-β peptide (Aβ), a peptide
central to AD pathology, Aβ, in turn, may promote formation of atherosclerotic
lesions through vascular oxidative stress and endothelial dysfunction leading to
additional vascular damage. Here, we briefly review evidence suggesting that impaired
clearance of Aβ is an additional, simultaneously occurring mechanism by which
AD and cerebrovascular disease may be causally linked. We examine the literature
supporting mechanisms by which flow-limiting large-artery stenosis, arterial stiffening
and microvascular dysfunction could contribute to AD pathophysiology by impairing
Aβ clearance and elevating brain levels of Aβ. Finally, we highlight the need for
further research to improve our understanding of the complex interactions of AD and
atherosclerosis with Aβ clearance, which may ultimately serve to guide the development
of novel diagnostic and therapeutic approaches for this devastating and highly prevalent
condition.
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Introduction
Alzheimer’s Disease (AD) remains a major cause of morbidity and mortality worldwide.
Recent estimates suggest that the public health burden attributable to AD will only
continue to increase, with over 100 million AD cases projected worldwide by the year 2050
(Brookmeyer et al., 2007). Despite evidence that the prevalence of AD has declined in the
last two decades (Larson et al., 2013), the anticipated expansion of the aging population is
predicted to offset such decline. As such, there is a pressing need to develop new approaches
to mitigate the enormous societal impact of AD-related dementia. To this end, an important
strategy is pinpointing specific pathophysiologic mechanisms involved in AD development,
including the identification of potentially modifiable risk factors commonly seen in aging
populations (Norton et al., 2014).
One such potential risk factor strongly associated with the development and progression
of AD is atherosclerosis of the cerebral arteries. Atherosclerosis has long been implicated
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in the pathogenesis of dementia, including theories existing
since the early 1900s in which ‘‘hardening of the arteries’’
was hypothesized to play a central role in the development of
dementia (Iadecola, 2013). With the identification in the 1980’s
of amyloid-β peptide (Aβ) as the main constituent of amyloid
deposits in the cerebral vasculature (amyloid angiopathy) and
in the brain parenchyma (amyloid plaque) in AD (Glenner and
Wong, 1984; Kang et al., 1987), the emphasis shifted towards
AD neuropathology as the major cause of dementia (Bowler,
2007). Subsequent investigations of the association between
vascular factors and AD focused on the mechanisms by which
atherosclerosis of cerebral vessels and its effects on cerebral
perfusion might contribute to AD pathology by increasing
Aβ production and/or reducing its clearance from the brain
(Iadecola, 2010). Recent evidence suggests that Aβ may also
promote cerebrovascular atherosclerosis, resulting in a vicious
circle whereby vascular damage and Aβ accumulation interact
synergistically to increase brain dysfunction and damage. Our
purpose here is to briefly review existing epidemiologic and
clinical-pathological evidence which supports the coexistence
and pathogenic overlap of AD and atherosclerosis. Since both
large and small vessel pathology has been associated with AD,
in addition to large-vessel atherosclerosis involving the large
extracranial arteries and circle of Willis, we will also discuss
microvascular pathology affecting smaller arteries and arterioles.
Finally, we will examine pathways by which cerebrovascular
damage might impair Aβ clearance and Aβ may promote
atherogenesis, and their import for the treatment and prevention
of AD.
Evidence Supporting a Shared Link
between Atherosclerosis and AD
Epidemiologic Evidence and Imaging
Population-based epidemiologic data has significantly expanded
our understanding that the pathogenesis of AD is broader
in scope than might be apparent from neuronal studies
focused exclusively on Amyloid Precursor Protein (APP) and
Aβ. There is an extensive body of evidence showing that
the risk factors for atherosclerotic vascular disease, including
diabetes, hypercholesterolemia, and aging, are also risk factors
for the development of AD (Breteler, 2000). For example,
a prospective cohort study of over 1100 subjects without
dementia at baseline showed that the presence of diabetes,
hypertension, heart disease, and current smoking were associated
with a higher risk of developing AD, and that the presence
of three or more of these risk factors synergistically conferred
a 3.4-fold increased risk of developing clinically apparent AD
(Luchsinger et al., 2005). Additionally, in the Rotterdam Scan
Study (Vermeer et al., 2003), in which 1015 participants were
scanned with magnetic resonance imaging (MRI), investigators
found that ‘‘silent’’ brain infarcts resulted in an almost 2.3-
fold increased risk of dementia during a mean 3.6 year
follow-up, with the majority of cases showing clinical evidence
of AD.
More recent work has shown that specific vascular risk
factors are not only predictive of clinical AD, but also of
amyloid accumulation. Using an in vivo cerebral amyloid
deposition measure with 11C-Pittsburgh compound B (PIB)
positron emission tomography (PET), Reed et al. showed that
an increased Framingham Coronary Risk Profile independently
accounted for significant variance in amyloid deposition in the
brain in a cross-sectional study in adults with normal cognition
or mild cognitive impairment (Reed et al., 2012). In similar
studies using PIB based imaging techniques, hypertension,
high low-density lipoprotein cholesterol, and low high-density
lipoprotein cholesterol have all been isolated as specific vascular
risk factors that enhance amyloid deposition in the brain
(Rodrigue et al., 2013; Reed et al., 2014). In light of such
mounting data, in a recent analysis Barnes and Yaffe have
suggested that up to half of the AD cases worldwide (over 17
million) are potentially attributable to vascular risk factors and
that a 10–25% reduction of these risk factors could prevent
over a million cases of AD cases worldwide (Barnes and Yaffe,
2011).
Clinical-pathological Evidence
Additional clinical-pathological studies have shown a link
between ischemic lesions and AD. For example, in the Nun
Study (Snowdon et al., 1997), an autopsy study of the brains
of 61 women with neuropathologic evidence of AD, those
subjects with concurrent brain infarcts had poorer cognitive
function and a higher prevalence of dementia than those
without infarcts. In particular, participants who had lacunar
infarcts in the basal ganglia, thalamus, or deep white matter
had an almost 20-fold increased odds of dementia compared
to those without infarcts. Conversely, in the 41 subjects
without AD, the presence of brain infarcts was only weakly
associated with cognitive impairment and dementia. Although
the vascular pathology underlying the ischemic lesions was
not established, these findings suggest that cerebrovascular
disease plays a role in determining the clinical expression of
AD. In a large cross-sectional study (Honig et al., 2005), the
authors analyzed data from over 1000 subjects from the United
States National Alzheimer’s Coordinating Center Database and
found that atherosclerotic disease of the large cerebral arteries
was strongly associated with neuritic plaque burden, a major
pathologic manifestation of AD. However, other studies failed
to report an association of AD pathology with cerebrovascular
atherosclerosis (Dolan et al., 2010; Zheng et al., 2013), a
discrepancy attributed to differences in patient selection (Chui
et al., 2012). Nevertheless, the collective evidence lends support
to the notion that ischemic brain lesions worsen the cognitive
deficits in AD, and strongly suggest that vascular insufficiency
and AD pathology are inextricably linked in the expression
of the dementia (Iadecola and Gorelick, 2003; Toledo et al.,
2013).
Further clinical studies have focused on more direct measures
of atherosclerotic vascular disease. An autopsy study (Roher
et al., 2003) of 32 AD patients and 22 nondemented controls
analyzed atherosclerotic disease patterns in the circle of
Willis. In this study, intracranial stenoses were determined
based on histopathologic analysis of arteries cut into cross-
sections and examined under a dissecting microscope for
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atheroma-related vessel narrowing. It was found that in AD
patients the circle of Willis arteries exhibited significantly more
numerous and severe intracranial stenoses than in nondemented
controls. Moreover, this study found that a composite measure
of the intracranial stenosis burden significantly correlated
with multiple metrics of AD neuropathology, including the
plaques, tangles, and Braak stage score (Roher et al., 2003).
Larger subsequent neuropathological studies (Beach et al.,
2007) confirmed the strong, independent association between
intracranial atherosclerosis and AD after correcting for age,
gender, and apolipoprotein E4 allele status. Most recently,
in a large cohort of 1000 cases with gross and microscopic
neuropathological data, investigators found that 77% of AD
subjects had grossly apparent circle of Willis atherosclerosis,
a rate which was significantly higher than that of normal
subjects or of subjects with non-AD disease (Yarchoan et al.,
2012). Although multiple histopathologic studies support a
relationship between AD and large vessel atherosclerosis,
the extent to which AD is associated with small vessel
arteriolosclerotic changes, defined as concentrically thickened
and/or dysmorphic arterioles, remains less clear. For example,
a recent study failed to detect arteriolosclerosis in the frontal
cortex of AD brains (Neltner et al., 2014). Another study
demonstrated evidence of hypoxia-linked gene expression
in the brain of patients with AD (Thomas et al., 2015).
The effect was not associated with structural alterations
of arterioles or amyloid angiopathy, but with increased
expression of the vasoconstrictor endothelin-1. Although the
contribution of hypoperfusion from large artery atheroma
could not be assessed, these observations provide evidence
that the brain of AD patients is under hypoxic stress, which
has important implications for Aβ accumulation (see next
section).
Beyond these clinical-pathological studies, modern structural
neuroimaging allows for both direct and indirect assessment of
macroangiopathic atherosclerotic disease (Gupta et al., 2012).
Historically, in vivo clinical assessment of vascular abnormalities
has relied on arterial catheterization and angiographic studies
requiring the administration of iodinated contrast, which
though highly accurate in assessing luminal narrowing, is
invasive, carries significant potential risks, and cannot provide
direct visualization of plaque or the arterial vessel wall.
More recently developed techniques, now widely used in
clinical practice, such as magnetic resonance angiography
(MRA) and computed tomographic angiography (CTA), are
cross-sectional imaging techniques for the visualization of
major intracranial and extracranial arterial structures, and for
delineation between vessel wall, vessel lumen, and atherosclerotic
plaque (Gupta et al., 2012). In addition, techniques involving
measurement of Cerebral Blood Flow (CBF) including CT
and MR perfusion or intravascular flow velocities, such as
transcranial Doppler and carotid sonography, allow for the
detection of hemodynamic abnormalities that provide indirect
evidence of vessel pathology, which in aging adults is most
commonly related to atherosclerotic vessel narrowing (Gupta
et al., 2012). In more recent work employing one such
technique, Roher et al. (2011) used transcranial Doppler (TCD)
ultrasound in 42 AD subjects and 50 nondemented controls
to measure pulsatility indices of the large intracranial arteries
of the circle of Willis, defined as the transcranial Doppler-
determined peak systolic velocity minus the end-diastolic
velocity, divided by the overall mean flow velocity (Roher et al.,
2011). Confirming earlier studies (Ruitenberg et al., 2005),
AD patients were found to have decreased arterial mean flow
velocity and increased pulsatility index in the vascular territories
supplied by the circle of Willis. This study also found that
there were decreased diastolic flow velocities in the major
extracranial arteries in the neck (the carotid arteries) in AD
patients vs. nondemented controls, presumably related to loss
of elastic capacity secondary to wall stiffening of large cerebral
arteries.
In an attempt to link together physiologic measures
of arteriosclerosis with imaging markers of AD pathology,
investigators recently studied in vivo amyloid deposition and
its relationship to arterial stiffness in 81 elderly nondemented
individuals (Hughes et al., 2014). In this longitudinal cohort
study, PET with PIB was used to evaluate for the presence of
amyloid both at baseline and at a 2-year follow up scan. In
addition, arterial stiffness was measured using a noninvasive
automated waveform analyzer in both central and peripheral
vascular beds. The investigation showed that the increase in
proportion of amyloid positive subject from 48% to 75% was
strongly associated with increases of arterial stiffness over
time. Therefore, arterial stiffness is strongly associated with
the progressive deposition of Aβ in the brain, a conclusion
also supported by prior work showing associations between
AD and peripheral vascular disease (Newman et al., 2005),
and carotid artery intima-media thickness (Hofman et al.,
1997; Gorgone et al., 2009). The interplay between CBF
impairment, increased arterial rigidity, and AD has been
confirmed by several similar investigations (Alsop et al.,
2000; van Oijen et al., 2007; Dai et al., 2009; Jurasic
et al., 2009; Silvestrini et al., 2009). These data, collectively,
suggest that noninvasive assessments of macroangiopathic
atherosclerosis with modern neuroimaging techniques might
aid in identifying those patients potentially at greatest risk of
developing dementia, including AD, and who could benefit
most from strict vascular risk factor control and vasoprotective
therapies.
Mechanisms Linking Atherosclerosis
and AD
Vascular Insufficiency and APP Processing
Persistent brain hypoperfusion, as a result of both flow-
limiting large vessel atherosclerotic stenoses and increased
vascular stiffness resistance of the small and large vessels,
has been linked to the pathophysiologic cascade leading
to AD pathology. Brain hypoxia, which can result from
advanced atherosclerosis, has been shown to significantly
increase the cleavage of Aβ from the APP via upregulation
of the β- and γ-secretase enzymatic pathways (Sun et al.,
2006; Tesco et al., 2007; Zhang et al., 2007; Li et al., 2009).
Experimental studies have confirmed the role of hypoperfusion
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in exacerbating amyloid pathology. For example, chronic
cerebral hypoperfusion secondary to mechanically-induced
bilateral common carotid artery stenosis in mice has been
shown to cause an accelerated deposition of leptomeningeal Aβ
and an increased incidence of cortical microinfarcts compared
to mice without carotid stenosis (Okamoto et al., 2012).
Consistent with a role of hypoxia-ischemic in promoting
Aβ production, plasma Aβ has been reported to increase
after cardiac arrest in humans (Zetterberg et al., 2011).
Furthermore, experimental hypertension, which compromises
cerebral perfusion, aggravates vascular dysfunction and enhances
amyloidogenic APP processing by promoting β-secretase activity
(Faraco et al., 2015).
The deleterious effects of Aβ on cerebrovascular function
are well-characterized and include increased arterial
vasoconstriction, reduction in resting CBF, attenuated
endothelium-dependent vasodilatation, and reduction in
the extent of CBF increase evoked by neural activity (Thomas
et al., 1996; Niwa et al., 2000a,b, 2001; Iadecola, 2003a, 2004)
Similar cerebrovascular dysfunction has been observed in
mice in which brain Aβ is increased by overexpression of
mutated APP (Iadecola et al., 1999; Niwa et al., 2002a,b). These
observations have led to the hypothesis that Aβ in addition
to its well established deleterious effects on neuronal activity,
also impairs cerebral perfusion, setting the stage for ischemic
brain injury (Iadecola, 2003b). In support of this hypothesis,
mice overexpressing APP are more susceptible to cerebral
ischemia (Zhang et al., 1997), whereas the incidence of ischemic
stroke is increased in AD patients (Chi et al., 2013; Tolppanen
et al., 2013). At the same time, as reviewed above, hypoxia
may increase the rate of cleavage of Aβ from APP and tau
phosphorylation (Koike et al., 2010). Therefore, the deleterious
vascular effects of Aβ are likely to act synergistically with
large artery atherosclerosis to aggravate cerebral perfusion,
which, in turn, promotes amyloidogenesis by increasing APP
cleavage.
Atherosclerosis and Aβ Clearance
Though there has been significant focus on the increase in Aβ
production caused by the downstream effects of atherosclerosis
of the large and small cerebral arteries, there has been
increasing evidence suggesting that impairment of Aβ clearance
may also be an additional link between atherosclerosis and
AD neuropathology. Mechanisms that play a central role in
the clearance of Aβ from the brain include degradation via
neprilysin and other Aβ-degrading enzymes, CSF reabsorption,
and removal through vascular mechanisms, which include
transfer into the bloodstream via the lipoprotein receptor-
related protein-1 and perivascular drainage (Miners et al.,
2008; Bell and Zlokovic, 2009). The perivascular pathway is
involved in the drainage of soluble metabolites, proteins and
peptides from the brain, which ultimately flows into the cervical
lymph nodes (Hawkes et al., 2011; Carare et al., 2013). In
this pathway, interstitial fluid enters the perivascular space
surrounding the vascular basement membrane (Virchow-Robin
Space) by bulk flow (Hawkes et al., 2014). Because such solute
transport occurs in blood vessel walls in the opposite direction
of blood flow, the pressure gradient driving such an exchange
is uncertain. Furthermore, studying the molecular transports
along these perivascular pathways has been challenging to
investigate experimentally, given the small size and rapidity
of such drainage in vivo (Hawkes et al., 2014). However, the
relative contribution of the major Aβ clearance pathways has
recently been estimated in humans (Roberts et al., 2014). It was
found that 50% of Aβ clearance could be attributed to CSF and
vascular-perivascular pathways (Roberts et al., 2014), attesting
to the importance of vascular Aβ clearance also in the human
brain.
Studies using mathematical modeling of perivascular solute
transport in the brain strongly suggest that the driving force
for such solute transfer is the recoil or reflection wave of the
arterial wall after normal cardiac pulse wave (Schley et al.,
2006; Wang and Olbricht, 2011). For example, in a model
assuming that solute drainage occurs through a thin layer
between astrocytes and endothelial cells (Schley et al., 2006),
the successful drainage of solutes such as Aβ likely occurs in
each pulse cycle during discrete, transient time periods when
fluid and solutes are driven in the perivascular space in the
opposite direction of blood flow. Moreover, in this model, it is
likely that the efficient drainage of interstitial fluid requires some
attachment of solutes to the lining of the perivascular space in
order to produce a one-way valve effect. This model predicts
that reductions in the amplitude of vessel wall movement in
disease states, such as might be seen in hypoperfusion from
proximal arterial stenosis or wall-stiffening in microangiopathic
arteriosclerosis, will prolong solute attachment time to the
perivascular space lining. In such a scenario, in the case of
Aβ, for example, these reductions in the amplitude of vessel
wall movement would reduce Aβ clearance and might therefore
precipitate the type of vascular and parenchymal accumulation
of Aβ seen in AD. In another analysis of fluid mechanics in
the perivascular space (Wang and Olbricht, 2011), mathematical
models also showed that the peristaltic motion of blood vessel
walls are needed to facilitate fluid and solute transport in
the perivascular space. These modeling data are consistent
with the distribution of Aβ in the walls of large cortical
and leptomeningeal arteries in cerebral amyloid angiopathy
which support the notion that Aβ is likely deposited in the
perivascular pathways of interstitial fluid drainage from the
brain (Hawkes et al., 2014). Experimental models with mice
also support this hypothesis, with experimental data (Hawkes
et al., 2011) suggesting that the Aβ injected into the interstitial
fluid of adult mice distribute in the basement membrane in
the same pattern as cerebral amyloid angiopathy in humans,
which can in turn further impair perivascular drainage in the
brain.
More recently, new MRI technology has been used to
demonstrate in vivo the perivascular pathways, which exist for
CSF and interstitial fluid exchange that enable solute clearance
from the brain. For example, using dynamic contrast-enhanced
MRI of the rat brain, a recent study confirmed that CSF flow
occurs through major para-arterial pathways and that exchange
between the CSF and interstitial space occurs in molecular-
size dependent fashion (Iliff et al., 2013). Similarly, using both
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in vivo and ex vivo fluorescence microscopy, in a separate
study investigators studied interstitial solute clearance after Aβ
injection into the brain parenchyma of mice (Kress et al., 2014).
Compared to relatively young wild-typemice, the clearance of Aβ
from the brain parenchymawas impaired by 40% in old wild-type
mice. Importantly, these investigators found a 27% reduction in
vessel wall pulsatility of intracortical arterioles associated with
the decline in Aβ solute exchange, suggesting that arterial wall
stiffening may play a central role in allowing for the successful
clearance of Aβ. Whether impaired clearance of Aβ may be
occurring secondary tomyocyte loss in the absence of thrombotic
plaques per se requires further investigation, potentially with
similar advanced MRI techniques using animal models.
When these animal and theoretical modeling data are viewed
in light of the human clinical and epidemiologic evidence
linking AD and atherosclerosis, impaired clearance of Aβ via
the perivascular drainage pathways becomes a highly plausible,
additional mechanism by which Aβmay exert deleterious effects
on brain vascular biology. Both distal flow reduction from
macroangiopathic atherosclerotic narrowing (such as would be
seen with carotid stenosis) and vascular stiffening would be
plausible mechanisms by which atherosclerosis could impair the
driving force needed to efficiently clear Aβ via the perivascular
routes. Clearly, until methods of measuring Aβ clearance
in humans (Roberts et al., 2014) are applied more widely,
much of the evidence supporting this relationship between
atherosclerosis and Aβ clearance remains largely inferential
and requires additional study. Moreover, potential mechanisms
for improving Aβ clearance, such as the use of vasoactive
agents that increase arterial pulsatility (Iliff et al., 2013),
represent novel therapeutic strategies also worthy of further
investigations.
While more precise diagnostic and therapeutic strategies
focused on Aβ clearance are being studied, on a broader
scale, improving our understanding of the mechanisms linking
atherosclerosis with AD remains critically important. Such
work should serve to increase the urgency and resources with
which cardiovascular diseases in general are treated, given that
atherosclerosis remains both underdiagnosed and undertreated
(Bhatt et al., 2006). Preliminary work to date has been promising,
with studies suggesting that control of vascular risk factors may
reduce MRI defined white matter lesions in AD and, at least
early in the disease course, may delay AD progression (Rosenberg
et al., 2008; Deschaintre et al., 2009; Richard et al., 2010; Valenti
et al., 2014). Furthermore, the recently reported reduction in the
incidence of AD has been attributed in large part to a better
control of vascular risk factors (Larson et al., 2013).
Aβ and Atherosclerosis
Whereas, as discussed above, atherosclerosis and related vascular
insufficiency can promote Aβ accumulation, there is converging
evidence suggesting that Aβ can promote atherogenesis. Autopsy
data from human brains have shown that amongst non-
demented elderly subjects, a high burden of atherosclerosis
in the circle of Willis is strongly associated with increased
levels of Aβ42 compared to subjects with lesser degrees
of cerebral atherosclerosis, even though levels of β-secretase
are comparable between high and low-atherosclerosis groups
(Sadleir et al., 2013). Though the cause of such brain Aβ
elevations is uncertain, several lines of investigation suggest
that Aβ itself is atherogenic. Early work supporting this
hypothesis includes the finding that Aβ and APP are found
in the microvasculature surrounding advanced human carotid
artery plaque (De Meyer et al., 2002). The latter study also
found that platelet-derived APP is proteolytically converted
to Aβ and that this pathway results in inducible nitric
oxide synthase induction and increased macrophage activation,
findings which suggest that Aβ may play a key role in the pro-
inflammatory cascade of atherosclerosis. More recent work in
mouse models (Tibolla et al., 2010; Caravaggio et al., 2013)
has further supported the role of Aβ in the development of
atherosclerotic plaque. Caravaggio et al. (2013) for example,
used an insulin-degrading enzyme and lipoprotein receptor-
deficient mouse model to show that insulin-degrading enzyme
deficiency results not only in larger atherosclerotic lesions but
also increased levels of Aβ within these plaques. Similarly,
the work of Tibolla et al. (2010) in which a mouse model
with central nervous system-restricted APP overexpression
was studied, suggests that the inflammatory effects of APP
overexpression can lead to aortic atherosclerosis even before
brain parenchymal Aβ deposition. These findings are consistent
with the hypothesis that while atherosclerosis-induced vascular
insufficiency increases Aβ production and accumulation, Aβ,
in turn, promotes atherogenesis (Iadecola, 2003a). However,
the available data is still limited and future studies are
warranted to further assess the mechanisms by which Aβ
promotes atherosclerotic plaque formation in order to improve
FIGURE 1 | Potential mechanisms linking atherosclerosis to amyloid
pathology. Atherosclerosis promotes brain Aβ accumulation by reducing
cerebral blood flow (oligemia) leading to hypoxia, which increases Aβ
production by activating β-secretase. In turn, Aβ promotes atherogenesis
through endothelial dysfunction, oxidative stress, and inflammation.
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our understanding of the causal role which Aβ plays in
atherogenesis.
Conclusions
Atherosclerosis and AD, independently, are two of the largest
public health burdens in aging populations, and together, appear
to act in an additive or potentially synergistic fashion based
on mounting epidemiologic, clinical and experimental evidence
(Figure 1). The vascular biology of Aβ figures prominently in
most theories linking atherosclerosis with the development and
progression of AD. While increased production of Aβ may link
cerebral hypoperfusion to AD, impaired clearance of Aβ has
emerged an additional mechanism, which may be occurring
simultaneously and act in concert to enhance Aβ deposition.
Thus, large vessel flow-limiting stenosis, macro- and micro-
angiopathic arterial stiffening and neurovascular dysregulation
could also play a role in AD pathophysiology by aggravating
the hypoperfusion, impairing Aβ clearance and elevating brain
levels of Aβ. A link between Aβ and the process of atherogenesis
is also emerging, whereby Aβ could promote formation of
atherosclerotic lesions leading to additional vascular damage.
Further studies are now warranted to investigate this recently
appreciated mechanistic link between AD and cerebrovascular
disease, and new methods to investigate Aβ deposition and
trafficking in the human brain promise to advance the field
forward. In the meantime, in the absence of effective therapies to
target Aβ, tau and their deleterious effects, the evidence suggests
that the optimal management of vascular risk factors may be
the most beneficial means of reducing the morbidity not only
of cardiovascular ischemic events, but AD as well. This course
of action has recently been validated by a study in which diet,
exercise, and vascular risk factor monitoring were found to slow
down the progression of dementia (Ngandu et al., 2015).
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